14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Tuesday, 9th Jan 2024 ZYNE stock ended at $1.30. During the day the stock fluctuated 0% from a day low at $1.30 to a day high of $1.30.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Zynerba Pharmaceuticals prices

Date Open High Low Close Volume
Jan 29, 2016 $6.37 $6.72 $6.35 $6.62 34 100
Jan 28, 2016 $7.26 $7.26 $6.20 $6.30 155 000
Jan 27, 2016 $7.60 $8.01 $7.05 $7.15 32 100
Jan 26, 2016 $8.32 $8.33 $7.61 $7.66 63 100
Jan 25, 2016 $8.90 $9.80 $8.13 $8.16 27 700
Jan 22, 2016 $9.68 $9.68 $8.99 $9.04 55 800
Jan 21, 2016 $9.28 $10.00 $8.84 $9.45 31 700
Jan 20, 2016 $9.09 $9.74 $8.15 $9.40 66 500
Jan 19, 2016 $8.15 $10.84 $7.55 $9.41 128 200
Jan 15, 2016 $8.27 $8.44 $7.70 $7.86 26 100
Jan 14, 2016 $8.06 $8.66 $7.42 $8.60 48 400
Jan 13, 2016 $8.86 $9.17 $7.90 $8.04 63 100
Jan 12, 2016 $8.60 $8.82 $8.19 $8.43 44 100
Jan 11, 2016 $8.80 $8.80 $8.08 $8.54 59 800
Jan 08, 2016 $8.78 $9.35 $8.72 $8.77 45 700
Jan 07, 2016 $8.99 $8.99 $8.54 $8.75 38 700
Jan 06, 2016 $9.01 $9.38 $8.92 $9.10 55 900
Jan 05, 2016 $9.60 $9.78 $9.25 $9.25 40 900
Click to get the best stock tips daily for free!

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba P... ZYNE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT